Repare Therapeutics INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
BVF Partners and affiliated entities report ceasing beneficial ownership of Repare Therapeutics Inc. shares following its acquisition by XenoTherapeutics.
Biotechnology Value Fund and affiliates, holding 24% of Repare Therapeutics, sign voting agreements to support Xeno Acquisition Corp.'s takeover bid.
Versant Venture Capital and its affiliated funds have substantially decreased their beneficial ownership in Repare Therapeutics Inc. through a series of share sales in November 2025.
A group of investment entities and individuals led by MPM BioImpact LLC have significantly reduced their beneficial ownership in Repare Therapeutics Inc. through open market sales, falling below the 5% reporting threshold.
An investment group led by MPM BioImpact LLC and its affiliates, including managing directors Ansbert Gadicke, Luke Evnin, and Todd Foley, has significantly reduced its beneficial ownership in Repare Therapeutics Inc. through a series of open market share sales in January 2025.
A group of investment entities and individuals affiliated with MPM BioImpact LLC has significantly reduced their beneficial ownership in Repare Therapeutics Inc. through recent open market share sales.